ClinicalTrials.gg
CompletedNCT00910910ORIGINUpdated Jul 9, 2019Results posted

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

A Phase 3 interventional study of Lenalidomide and Chlorambucil in B-Cell Chronic Lymphocytic Leukemia, sponsored by Celgene. Completed at 165 sites in 27 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2019-07-09.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 5 under way, none of them phase 3. Lenalidomide · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
Largest of 77
450 · median 29
Started
2009
with 9 others
Phase 3
3 of 78
none open now
Registered
29th of 78
by date
Lead sponsor
4 of 78
Celgene

Among the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell, this one has the largest enrollment of the 77 interventional ones that give a count, is one of 10 that started in 2009, is one of 3 in phase 3, and was the 29th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of lenalidomide as a first line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia. This study will compare the effects (good and bad) of lenalidomide with chlorambucil.

Read the detailed description

After notification from the US Food and Drug Administration (FDA) on 12 July 2013, Celgene agreed to discontinue the lenalidomide treatment for all patients due to an imbalance in the number of deaths in patients treated with lenalidomide versus patients treated with chlorambucil. No specific causality for this imbalance has been identified to date. Investigators were instructed to immediately discontinue all participants from experimental lenalidomide treatment and inform their patients accordingly. Participants on the Chlorambucil arm may continue up to 12 months (13 cycles) with the last participant completing in March 2014. All randomized participants will continue to be followed for overall survival and secondary primary malignancies.

03

Conditions studied

  • B-Cell Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must sign an form.
  2. Age ≥ 65 years
  3. Must be able to adhere to the study visit schedule and other protocol requirements.
  4. Must have a documented diagnosis of B-cell CLL.
  5. Must have an (ECOG) performance status score of ≤2.
  6. Must agree to follow pregnancy precautions as required by the protocol.
  7. Must agree to receive counseling related to teratogenic and other risks of lenalidomide.
  8. Must agree not to donate blood or semen as defined by the protocol

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment for B-cell CLL.
  2. Any medical condition, that would prevent the subject from signing the form.
  3. Active infections requiring systemic antibiotics.
  4. Systemic infection that has not resolved > 2 months prior to initiating lenalidomide
  5. Pregnant or lactating females.
  6. Participation in any clinical study or having taken any therapy within 28 days.
  7. Known presence of alcohol and/or drug abuse.
  8. Central nervous system (CNS) involvement.
  9. Prior history of , other than CLL, unless the subject has been free of the disease for ≥3 years. Exceptions include the following:

    • Basal cell carcinoma of the skin
    • Squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix
    • Carcinoma in situ of the breast
    • Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)
  10. History of renal failure requiring dialysis.
  11. Known (HIV), Virus (HBV) and/or Virus (HCV) infection.
  12. Prior therapy with lenalidomide.
  13. Evidence of TLS at screening
  14. Presence of specific hematology and/or chemistry abnormalities
  15. Uncontrolled hyperthyroidism or hypothyroidism
  16. Venous thromboembolism within one year
  17. ≥ Grade-2 neuropathy
  18. Uncontrolled hemolytic anemia or thrombocytopenia
  19. Disease transformation [i.e. Richter's Syndrome (lymphomas) or prolymphocytic leukemia]
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (actual)

Study arms

  • Experimental
    1 - Lenalidomide

    1 - Lenalidomide

    Drug: Lenalidomide

  • Active comparator
    2- Chlorambucil

    2- Chlorambucil

    Drug: Chlorambucil

Interventions

  • For patients with normal renal function (defined as CrCl ≥ 60 mL/min), 5 mg once daily on Days 1 through 28 of the first 28-day cycle, 10 mg once daily on Days 1 through 28 starting at the second cycle, 15 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first. For patients with moderate renal impairment (defined as CrCl ≥ 30 to \< 60 mL/min), 2.5 mg once daily on Days 1 through 28 of the first 28-day cycle, 5 mg once daily on Days 1 through 28 starting at the second cycle, 7.5 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.

    Also known as: Revlimid

  • Patients assigned to the chlorambucil arm will receive oral chlorambucil tablets at 0.8 mg/kg on Days 1 and 15 of each 28-day cycle for a total duration of 12 months (approximately 13 cycles).

    Also known as: Leukeran

06

What researchers measure

Primary outcomes

  1. Kaplan-Meier Estimate of Progression Free Survival (PFS)

    Progression-free survival was defined as the time from randomization to the first documented progression confirmed per investigator's assessment or death due to any cause on study, whichever occurred first. The progression date was assigned to the earliest time when any progression was observed without prior missing assessments. If withdrawal of consent or lost to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression

    Time frame: From first dose of study drug to date of data cut-off of 18 Feb 2013; up to approximately 39 months

  2. Kaplan-Meier Estimate of Progression Free Survival (PFS) With a Later Cut-off Date of 14 March 2014

    Progression-free survival was defined as the time from randomization to the first documented progression confirmed per investigator's assessment or death due to any cause on study, whichever occurred first. Progressive disease included lymphadenopathy, an appearance of any new lesion such as enlarged lymph nodes (\> 1.5 cm), splenomegaly, hepatomegaly or other organ infiltrates, an increase by 50% or more in greatest determined diameter of any previous site or an increase by 50% or more in the sum of the product of diameters of multiple nodes. The progression date was assigned to the earliest time when any progression was observed without prior missing assessments. If withdrawal of consent or lost to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression.

    Time frame: From randomization to data cut off date of 31 March 2014; median follow up time for all participants was 12.6 months

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    AEs = any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, regardless of cause. Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity according to the following scale: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death

    Time frame: From randomization up to data cut-off of 18 Feb 2013; Up to approximately 39 months; maximum duration of exposure for Lenalidomide was 1086 days and 406 days for Chlorambucil

  2. Number of Participants With Adverse Events With a Later Cut-off Date of 31 March 2014

    AEs = any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, regardless of cause. Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity according to the following scale: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death

    Time frame: From randomization to the data cut-off date of 31 March 2014; Up to 53 months; maximum duration of exposure for Lenalidomide was 1140 days and 406 days for Chlorambucil

  3. Percentage of Participants With the Best Overall Response Based on the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Guidelines

    A best overall response rate is a CR, CRi, nPR or PR and is defined as: Complete Remission (CR): * No lymphadenopathy * No hepatomegaly or splenomegaly * Absence of constitutional symptoms * Polymorphonuclear leukocytes ≥ 1500/ul * No circulating clonal B-lymphocytes * Platelets \> 100,000/ul * Hemoglobin \> 11.0 g/dl * Normocellular \<30% lymphocytes, no B-lymphoid nodules; Incomplete Clinical Response (CRi): • CR without bone marrow biopsy confirmation. Nodular Partial Response (nPR): • CR with the presence of residual clonal nodules. Partial Response (PR) requires: * ≥ 50% decrease in peripheral blood lymphocyte count * ≥ 50% reduction in lymphadenopathy * ≥ 50% reduction in size of liver and/or spleen * 1 or more of the following: * Polymorphonuclear leukocytes ≥ 1500/ul * Platelets \>100,000/ul

    Time frame: Up to data cut-off date of 18 Feb 2013; approximately 39 months

  4. Percentage of Participants With a Best Overall Response Based on IWCLL Guidelines With a Later Cut-off Date of 31 March 2014

    A best overall response rate is a CR, CRi, nPR or PR and is defined as: Complete Remission (CR): * No lymphadenopathy * No hepatomegaly or splenomegaly * Absence of constitutional symptoms * Polymorphonuclear leukocytes ≥ 1500/ul * No circulating clonal B-lymphocytes * Platelets \> 100,000/ul * Hemoglobin \> 11.0 g/dl * Normocellular \<30% lymphocytes, no B-lymphoid nodules; Incomplete Clinical Response (CRi): • CR without bone marrow biopsy confirmation. Nodular Partial Response: • CR with the presence of residual clonal nodules. Partial Response requires: * ≥ 50% decrease in peripheral blood lymphocyte count * ≥ 50% reduction in lymphadenopathy * ≥ 50% reduction in size of liver and/or spleen * 1 or more of the following: * Polymorphonuclear leukocytes ≥ 1500/ul * Platelets \>100,000/ul

    Time frame: Up to data cut-off of 31 March 2014; approximately 53 months

  5. Kaplan-Meier Estimate for Duration of Response

    Duration of response was defined as the time from first nPR, PR, CRi, or CR to PD. Duration of response was censored at the last date that the patient was known to be progression-free for: 1) participants who had not progressed at the time of analysis; 2) participants who had withdrawn consent or were lost to follow-up prior to documentation of progression

    Time frame: Up to data cut-off of 18 Feb 2013; up to approximately 39 months

  6. Kaplan-Meier Estimate for Duration of Response With a Later Cut-off Date of 31 March 2014

    Duration of response was defined as the time from first nPR, PR, CRi, or CR to PD. Duration of response was censored at the last date that the patient was known to be progression-free for: 1) patients who had not progressed at the time of analysis; 2) patients who had withdrawn consent or were lost to follow-up prior to documentation of progression

    Time frame: Up to data cut-off of 31 March 2014; up to approximately 53 months

  7. Time to Response

    Time to response was calculated as the time from randomization to the first nPR, PR, CRi or CR based on IWCLL guidelines

    Time frame: Up to data cut-off of 18 Feb 2013; up to approximately 39 months

  8. Time to Response for a Later Cut-off Date of 31 March 2014

    Time to response was calculated as the time from randomization to the first nPR, PR, CRi or CR based on IWCLL guidelines

    Time frame: Up to data cut-off of 31 March 2014; up to approximately 53 months

  9. Kaplan Meier Estimate of Overall Survival

    Overall Survival is defined as the time between randomization and death from any cause.

    Time frame: Up to data cut off of 31 March 2014; median follow-up for all participants was 18.8 months

  10. Kaplan Meier Estimate for Overall Survival at the Final Analysis

    Overall Survival is defined as the time between randomization and death from any cause. Overall survival was censored at the last date that the subject was known to be alive for participants who were alive as of the data cutoff date and for participants who were lost to follow-up before death was documented.

    Time frame: Up to the last patient last visit date of 19 May 2018; median follow-up for all participants was 46.7 months

  11. Functional Assessment of Cancer Therapy-General to Create the FACT-Leukemia (FACT-Leu) Quality of Life Instrument

    The FACT-Leu scale is a valid, reliable, and efficient measure of leukemia-specific health-related quality of life for acute and chronic disease. The FACT-Leu is described as including 27 items that assess 17 physical symptoms (fevers, bleeding, general pain, stomach pain, chills, night sweats, bruising, lymph node swelling, weakness, tiredness, weight loss, appetite, shortness of breath, functional ability, diarrhea, concentration, and mouth sores) and 10 emotional/social concerns (frustration with activity limitation, discouraged by illness, future planning, uncertainty, worry about illness, emotional lability, isolation, infertility concern, family worry, and worry about infections).

    Time frame: Day 1 and once every 8 weeks

  12. Euro Quality of Life Five Dimension (EQ-5D) Questionnaire

    The standardized extended version of EQ-5D was designed for the collection of health state values using a visual analogue scale (VAS) rating scale - a vertical 20 cm visual analogue scale with the end points labeled best imaginable health state at the top and worst imaginable health state at the bottom having numeric values of 100 and 0 respectively. The participant is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.

    Time frame: Day 1 and once every 8 weeks

  13. Number of Participants and Types of Subsequent Anti-cancer Therapies Received Post Treatment

    Subsequent anti-cancer therapies administered to participants following the discontinuation of study drug (either Lenalidomide or Chlorambucil)

    Time frame: Up to the last patient last visit date of 19 May 2018; median follow-up for all participants was 46.7 months

Other outcomes

  1. Number of Participants Deaths During the Treatment and Survival Follow-Up Phase

    The number of study participants deaths during the treatment and follow-up phase

    Time frame: From the first dose of study drug up to the last patient last visit date of 19 May 2018; median follow-up for all participants was 46.7 months

07

Results

Posted Dec 21, 2016
Limitations and caveats
After notification by the US Food and Drug Administration on 12Jul2013, Celgene agreed to stop lenalidomide due to an imbalance in the number of deaths on the lenalidomide arm versus the chlorambucil arm; no causality for the imbalance was identified

Participant flow

118 sites randomized participants in Austria, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Columbia, Croatia, Czech Republic, Denmark, Hungary, Israel, Italy, the Netherlands, New Zealand, Poland, Portugal, Romania, Russia, South Africa, Slovakia, Spain, Serbia, the United Kingdom, and the United States of America

Participant flow — Overall Study
MilestoneLenalidomideChlorambucil
Started225225
Safety population224223
Completed01
Not completed225224
Withdrew: Adverse event6335
Withdrew: Pd without histologic change2723
Withdrew: Pd with histologic change02
Withdrew: Withdrawal by subject75
Withdrew: Lost to follow-up22
Withdrew: Death93
Withdrew: Protocol violation22
Withdrew: Completed 13 cycles of treatment0118
Withdrew: Other11432
Withdrew: Untreated before cycle 112

Outcome measures

PrimaryKaplan-Meier Estimate of Progression Free Survival (PFS)

Progression-free survival was defined as the time from randomization to the first documented progression confirmed per investigator's assessment or death due to any cause on study, whichever occurred first. The progression date was assigned to the earliest time when any progression was observed without prior missing assessments. If withdrawal of consent or lost to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression

Time frame:
From first dose of study drug to date of data cut-off of 18 Feb 2013; up to approximately 39 months
Reported as:
Median · months
Kaplan-Meier Estimate of Progression Free Survival (PFS)
monthsLenalidomideChlorambucil
Kaplan-Meier Estimate of Progression Free Survival (PFS)30.8 (18.7 to NA)23.0 (19.3 to 29.2)
Statistical analysis
  • Lenalidomide vs Chlorambucil · stratified log rank · p = 0.323 · Hazard ratio (hr): 1.21 · 90% CI 0.88 to 1.66Based on stratified Cox proportional hazards model comparing the hazard functions associated with treatment groups.
PrimaryKaplan-Meier Estimate of Progression Free Survival (PFS) With a Later Cut-off Date of 14 March 2014

Progression-free survival was defined as the time from randomization to the first documented progression confirmed per investigator's assessment or death due to any cause on study, whichever occurred first. Progressive disease included lymphadenopathy, an appearance of any new lesion such as enlarged lymph nodes (\> 1.5 cm), splenomegaly, hepatomegaly or other organ infiltrates, an increase by 50% or more in greatest determined diameter of any previous site or an increase by 50% or more in the sum of the product of diameters of multiple nodes. The progression date was assigned to the earliest time when any progression was observed without prior missing assessments. If withdrawal of consent or lost to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression.

Time frame:
From randomization to data cut off date of 31 March 2014; median follow up time for all participants was 12.6 months
Reported as:
Median · months
Kaplan-Meier Estimate of Progression Free Survival (PFS) With a Later Cut-off Date of 14 March 2014
monthsLenalidomideChlorambucil
Kaplan-Meier Estimate of Progression Free Survival (PFS) With a Later Cut-off Date of 14 March 201430.8 (18.7 to NA)21.4 (19.3 to 25.1)
Statistical analysis
  • Lenalidomide vs Chlorambucil · Log Rank · p = 0.967 (The p-value is based on a stratified log-rank test) · Cox proportional hazard: 0.99 · 90% CI 0.76 to 1.29Based on stratified Cox proportional hazards model comparing the hazard functions associated with treatment groups.
SecondaryNumber of Participants With Adverse Events (AEs)

AEs = any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, regardless of cause. Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity according to the following scale: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death

Time frame:
From randomization up to data cut-off of 18 Feb 2013; Up to approximately 39 months; maximum duration of exposure for Lenalidomide was 1086 days and 406 days for Chlorambucil
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsLenalidomideChlorambucil
≥ 1 TEAE202186
≥ 1 TEAE related to study drug183139
≥ 1 NCI CTC Grade 3-4 TEAE173117
Grade 3-4 adverse event related to any study drug14382
≥ 1 NCI CTC Grade 5 TEAE219
≥ Grade 5 adverse event related to any study drug61
≥ 1 Serious TEAE12976
≥ 1 Serious TEAE related to any study drug9546
≥1 TEAE leading to stopping either study drug6134
≥1 Related TEAE leading to stopping either drug3919
SecondaryNumber of Participants With Adverse Events With a Later Cut-off Date of 31 March 2014

AEs = any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, regardless of cause. Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity according to the following scale: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death

Time frame:
From randomization to the data cut-off date of 31 March 2014; Up to 53 months; maximum duration of exposure for Lenalidomide was 1140 days and 406 days for Chlorambucil
Reported as:
Number · participants
Number of Participants With Adverse Events With a Later Cut-off Date of 31 March 2014
participantsLenalidomideChlorambucil
≥ 1 TEAE216202
≥ 1 TEAE related to study drug194155
≥ 1 NCI CTC Grade 3-4 TEAE188131
Grade 3-4 adverse event related to any study drug15790
≥ 1 NCI CTC Grade 5 TEAE2111
≥ Grade 5 adverse event related to any study drug61
≥ 1 Serious TEAE14890
≥ 1 Serious TEAE related to any study drug10753
≥1 TEAE leading to stopping either study drug7042
≥1 Related TEAE leading to stopping either drug4623
SecondaryPercentage of Participants With the Best Overall Response Based on the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Guidelines

A best overall response rate is a CR, CRi, nPR or PR and is defined as: Complete Remission (CR): * No lymphadenopathy * No hepatomegaly or splenomegaly * Absence of constitutional symptoms * Polymorphonuclear leukocytes ≥ 1500/ul * No circulating clonal B-lymphocytes * Platelets \> 100,000/ul * Hemoglobin \> 11.0 g/dl * Normocellular \<30% lymphocytes, no B-lymphoid nodules; Incomplete Clinical Response (CRi): • CR without bone marrow biopsy confirmation. Nodular Partial Response (nPR): • CR with the presence of residual clonal nodules. Partial Response (PR) requires: * ≥ 50% decrease in peripheral blood lymphocyte count * ≥ 50% reduction in lymphadenopathy * ≥ 50% reduction in size of liver and/or spleen * 1 or more of the following: * Polymorphonuclear leukocytes ≥ 1500/ul * Platelets \>100,000/ul

Time frame:
Up to data cut-off date of 18 Feb 2013; approximately 39 months
Reported as:
Number · percentage of participants
Percentage of Participants With the Best Overall Response Based on the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Guidelines
percentage of participantsLenalidomideChlorambucil
Percentage of Participants With the Best Overall Response Based on the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Guidelines51.962.3
Statistical analysis
  • Lenalidomide vs Chlorambucil · Fisher Exact · p = 0.032 · Odds ratio (or): 0.65 · 95% CI 0.44 to 0.96
SecondaryPercentage of Participants With a Best Overall Response Based on IWCLL Guidelines With a Later Cut-off Date of 31 March 2014

A best overall response rate is a CR, CRi, nPR or PR and is defined as: Complete Remission (CR): * No lymphadenopathy * No hepatomegaly or splenomegaly * Absence of constitutional symptoms * Polymorphonuclear leukocytes ≥ 1500/ul * No circulating clonal B-lymphocytes * Platelets \> 100,000/ul * Hemoglobin \> 11.0 g/dl * Normocellular \<30% lymphocytes, no B-lymphoid nodules; Incomplete Clinical Response (CRi): • CR without bone marrow biopsy confirmation. Nodular Partial Response: • CR with the presence of residual clonal nodules. Partial Response requires: * ≥ 50% decrease in peripheral blood lymphocyte count * ≥ 50% reduction in lymphadenopathy * ≥ 50% reduction in size of liver and/or spleen * 1 or more of the following: * Polymorphonuclear leukocytes ≥ 1500/ul * Platelets \>100,000/ul

Time frame:
Up to data cut-off of 31 March 2014; approximately 53 months
Reported as:
Number · percentage of participants with response
Percentage of Participants With a Best Overall Response Based on IWCLL Guidelines With a Later Cut-off Date of 31 March 2014
percentage of participants with responseLenalidomideChlorambucil
Percentage of Participants With a Best Overall Response Based on IWCLL Guidelines With a Later Cut-off Date of 31 March 201460.970.2
Statistical analysis
  • Lenalidomide vs Chlorambucil · Fisher Exact · p = 0.047 · Odds ratio (or): 0.66 · 95% CI 0.45 to 0.98
SecondaryKaplan-Meier Estimate for Duration of Response

Duration of response was defined as the time from first nPR, PR, CRi, or CR to PD. Duration of response was censored at the last date that the patient was known to be progression-free for: 1) participants who had not progressed at the time of analysis; 2) participants who had withdrawn consent or were lost to follow-up prior to documentation of progression

Time frame:
Up to data cut-off of 18 Feb 2013; up to approximately 39 months
Reported as:
Median · weeks
Kaplan-Meier Estimate for Duration of Response
weeksLenalidomideChlorambucil
Kaplan-Meier Estimate for Duration of ResponseNA (131.1 to NA)105.3 (77.4 to 123.7)
Statistical analysis
  • Lenalidomide vs Chlorambucil · Log Rank · p = 0.826 · Hazard ratio (hr): 0.94 · 90% CI 0.58 to 1.52Based on stratified Cox proportional hazards model comparing the hazard functions associated with treatment groups
SecondaryKaplan-Meier Estimate for Duration of Response With a Later Cut-off Date of 31 March 2014

Duration of response was defined as the time from first nPR, PR, CRi, or CR to PD. Duration of response was censored at the last date that the patient was known to be progression-free for: 1) patients who had not progressed at the time of analysis; 2) patients who had withdrawn consent or were lost to follow-up prior to documentation of progression

Time frame:
Up to data cut-off of 31 March 2014; up to approximately 53 months
Reported as:
Median · weeks
Kaplan-Meier Estimate for Duration of Response With a Later Cut-off Date of 31 March 2014
weeksLenalidomideChlorambucil
Kaplan-Meier Estimate for Duration of Response With a Later Cut-off Date of 31 March 2014NA (149.4 to NA)87.1 (77.1 to 108.7)
Statistical analysis
  • Lenalidomide vs Chlorambucil · Log Rank · p = 0.149 · Cox proportional hazard: 0.71 · 90% CI 0.48 to 1.05Based on stratified Cox proportional hazards model comparing the hazard functions associated with treatment groups.
SecondaryTime to Response

Time to response was calculated as the time from randomization to the first nPR, PR, CRi or CR based on IWCLL guidelines

Time frame:
Up to data cut-off of 18 Feb 2013; up to approximately 39 months
Reported as:
Median · weeks
Time to Response
weeksLenalidomideChlorambucil
Time to Response8.6 (3.7 to 104.3)8.1 (3.7 to 52.7)
SecondaryTime to Response for a Later Cut-off Date of 31 March 2014

Time to response was calculated as the time from randomization to the first nPR, PR, CRi or CR based on IWCLL guidelines

Time frame:
Up to data cut-off of 31 March 2014; up to approximately 53 months
Reported as:
Median · weeks
Time to Response for a Later Cut-off Date of 31 March 2014
weeksLenalidomideChlorambucil
Time to Response for a Later Cut-off Date of 31 March 201410.4 (3.7 to 136.1)8.1 (3.7 to 68.7)
SecondaryKaplan Meier Estimate of Overall Survival

Overall Survival is defined as the time between randomization and death from any cause.

Time frame:
Up to data cut off of 31 March 2014; median follow-up for all participants was 18.8 months
Reported as:
Median · Months
Kaplan Meier Estimate of Overall Survival
MonthsLenalidomideChlorambucil
Kaplan Meier Estimate of Overall SurvivalNA (NA to NA)44.0 (37.3 to NA)
Statistical analysis
  • Lenalidomide vs Chlorambucil · Log Rank · p = 0.883 · Cox proportional hazard: 1.03 · 90% CI 0.73 to 1.46Based on stratified Cox proportional hazards model comparing the hazard functions associated with treatment groups.
SecondaryKaplan Meier Estimate for Overall Survival at the Final Analysis

Overall Survival is defined as the time between randomization and death from any cause. Overall survival was censored at the last date that the subject was known to be alive for participants who were alive as of the data cutoff date and for participants who were lost to follow-up before death was documented.

Time frame:
Up to the last patient last visit date of 19 May 2018; median follow-up for all participants was 46.7 months
Reported as:
Median · Months
Kaplan Meier Estimate for Overall Survival at the Final Analysis
MonthsLenalidomideChlorambucil
Kaplan Meier Estimate for Overall Survival at the Final Analysis74.3 (58.5 to 84.4)70.5 (57.1 to NA)
Statistical analysis
  • Lenalidomide vs Chlorambucil · stratified log rank · p = 0.709 · Cox proportional hazard: 1.06 · 90% CI 0.83 to 1.34Based on stratified Cox proportional hazards model comparing the hazard functions associated with treatment groups
SecondaryFunctional Assessment of Cancer Therapy-General to Create the FACT-Leukemia (FACT-Leu) Quality of Life Instrument

The FACT-Leu scale is a valid, reliable, and efficient measure of leukemia-specific health-related quality of life for acute and chronic disease. The FACT-Leu is described as including 27 items that assess 17 physical symptoms (fevers, bleeding, general pain, stomach pain, chills, night sweats, bruising, lymph node swelling, weakness, tiredness, weight loss, appetite, shortness of breath, functional ability, diarrhea, concentration, and mouth sores) and 10 emotional/social concerns (frustration with activity limitation, discouraged by illness, future planning, uncertainty, worry about illness, emotional lability, isolation, infertility concern, family worry, and worry about infections).

Time frame:
Day 1 and once every 8 weeks

No measurements were reported for this outcome.

SecondaryEuro Quality of Life Five Dimension (EQ-5D) Questionnaire

The standardized extended version of EQ-5D was designed for the collection of health state values using a visual analogue scale (VAS) rating scale - a vertical 20 cm visual analogue scale with the end points labeled best imaginable health state at the top and worst imaginable health state at the bottom having numeric values of 100 and 0 respectively. The participant is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.

Time frame:
Day 1 and once every 8 weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants and Types of Subsequent Anti-cancer Therapies Received Post Treatment

Subsequent anti-cancer therapies administered to participants following the discontinuation of study drug (either Lenalidomide or Chlorambucil)

Time frame:
Up to the last patient last visit date of 19 May 2018; median follow-up for all participants was 46.7 months
Reported as:
Number · participants
Number of Participants and Types of Subsequent Anti-cancer Therapies Received Post Treatment
participantsLenalidomideChlorambucil
Participants receiving additional CLL therapy125120
Participants receiving alkylating agents107106
Participants receiving antineoplastic aents9386
Participants receiving antimetabolites3424
Participants receiving corticosteroids2716
Participants receiving plant alkaloids2211
Participants receiving cytotoxic antibiotics103
Participants receiving immunosuppressants32
Participants receiving therapeutic products43
Participants receiving other unspecified products02
Antihistamine For Systemic Use11
Drugs for Peptic ulcer and Gastric Reflex10
Immunoglobulins12
Other Analgesics and Antipyretics11
Specific Antirheumatic Agents10
Antiemetics and Antinauseants01
Corticosteriods for Systemic Use01
Immunostimulants01
Other pre-specifiedNumber of Participants Deaths During the Treatment and Survival Follow-Up Phase

The number of study participants deaths during the treatment and follow-up phase

Time frame:
From the first dose of study drug up to the last patient last visit date of 19 May 2018; median follow-up for all participants was 46.7 months
Reported as:
Number · Participants
Number of Participants Deaths During the Treatment and Survival Follow-Up Phase
ParticipantsLenalidomideChlorambucil
Number of Participants Deaths During the Treatment and Survival Follow-Up Phase10195

Adverse events

Collected over All AEs were recorded by the Investigator(s) from first dose of study drug to 30 days after the treatment discontinuation visit. The median treatment duration was 263 days for lenalidomide and 362 days for chlorambucil.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide100/224 (44.6%)148/224 (66.1%)204/224 (91.1%)
Chlorambucil93/223 (41.7%)90/223 (40.4%)184/223 (82.5%)
Most frequent serious events
Showing 10 of 181
Most frequent serious events
EventLenalidomideChlorambucil
NEUTROPENIABlood and lymphatic system disorders54/22433/223
PNEUMONIAInfections and infestations24/2246/223
THROMBOCYTOPENIABlood and lymphatic system disorders19/22413/223
ANAEMIABlood and lymphatic system disorders18/22410/223
PYREXIAGeneral disorders10/2246/223
BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)5/2248/223
TUMOUR FLARENeoplasms benign, malignant and unspecified (incl cysts and polyps)8/2240/223
SQUAMOUS CELL CARCINOMA OF SKINNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/2247/223
FEBRILE NEUTROPENIABlood and lymphatic system disorders7/2243/223
AUTOIMMUNE HAEMOLYTIC ANAEMIABlood and lymphatic system disorders3/2244/223
Most frequent other events
Showing 10 of 36
Most frequent other events
EventLenalidomideChlorambucil
NEUTROPENIABlood and lymphatic system disorders126/22474/223
TUMOUR FLARENeoplasms benign, malignant and unspecified (incl cysts and polyps)85/22411/223
THROMBOCYTOPENIABlood and lymphatic system disorders72/22450/223
ANAEMIABlood and lymphatic system disorders69/22446/223
DIARRHOEAGastrointestinal disorders66/22432/223
FATIGUEGeneral disorders66/22453/223
NAUSEAGastrointestinal disorders33/22463/223
OEDEMA PERIPHERALGeneral disorders43/22416/223
RASHSkin and subcutaneous tissue disorders41/22419/223
COUGHRespiratory, thoracic and mediastinal disorders38/22421/223

Baseline characteristics

The Intent-to-Treat (ITT) population was defined as all participants who were randomized, independent of whether they received study treatment or not.

Age, Continuous
Age, Continuous(years)LenalidomideChlorambucilTotal
Mean73.0 ± 5.7273.3 ± 5.7273.1 ± 5.72
Sex: Female, Male
Sex: Female, Male(Participants)LenalidomideChlorambucilTotal
Female9383176
Male132142274
08

Study locations

165 sites
  • California Cancer Associates for Research and Excellence cCARE
    Escondido, California 92025, United States
  • Innovative Clinical Research Institute
    Whittier, California 90603, United States
  • The Hospital of Central Connecticut
    New Britain, Connecticut 06050, United States
  • Cancer Center of Central Connecticut
    Southington, Connecticut 06489, United States
  • University Hematology Oncology Inc.
    Centralia, Illinois 62801, United States
  • North Chicago VA Medical Center
    North Chicago, Illinois 60064, United States
  • Medical Consultants, PC
    Muncie, Indiana 47303, United States
  • Floyd Memorial Cancer Center of Indiana, a division of Floyd Memorial Hospital and Health Services
    New Albany, Indiana 47150, United States
  • Purchase Cancer Group
    Paducah, Kentucky 42001, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455-0392, United States
  • Saint Louis University Cancer Center
    Saint Louis, Missouri 63110, United States
  • Nevada Cancer Research Foundation
    Las Vegas, Nevada 89106, United States
  • Oncology and Hematology Associates, PA
    Denville, New Jersey 07834, United States
  • The Cancer Center, Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Somerset Hematology-Oncology Associates
    Somerville, New Jersey 08876, United States
  • Roswell Park Cancer Center
    Buffalo, New York 14263, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • Drexel University, College of Medicine
    Philadelphia, Pennsylvania 19102, United States
  • Pottstown Memorial Medical Center
    Pottstown, Pennsylvania 19464, United States
  • Berks Hematology-Oncology Associates
    West Reading, Pennsylvania 19611, United States
  • Geisinger Health System
    Wilkes-Barre, Pennsylvania 18711, United States
  • Charleston Hematology Oncology P.A.
    Charleston, South Carolina 29403, United States
  • South Carolina Cancer Specialists
    Hilton Head Island, South Carolina 29926, United States
  • Central Texas Veterans Health Care System
    Temple, Texas 76504, United States
  • Swedish Tumor Institute
    Seattle, Washington 98104, United States
  • Providence St. Mary Regional Cancer Center
    Walla Walla, Washington 99362, United States
  • Columbia St Marys Cancer Center
    Milwaukee, Wisconsin 53211, United States
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • IMVS
    Adelaide, South Australia 5000, Australia
  • Western Hospital
    Footscray, Victoria 3011, Australia
  • Royal Melbourne Hospital
    Melbourne, Victoria 3050, Australia
  • Flinders Medical Centre
    Bedford Park, 5042, Australia
  • St. Vincent Hospital
    Fitzroy, 3065, Australia
  • Nepean Hospital
    Kingswood, NSW, 2751, Australia
  • Calvary Mater Hospital
    Waratah, 2298, Australia
  • Westmead Hospital Australia
    Westmead, NSW2145, Australia
  • Universitaetsklinik Innsbruck
    Innsbruck, 6020, Austria
  • Medical University of Vienna Internalmedicine 1, Hematology
    Vienna, 1190, Austria
  • Institut Jules Bordet
    Brussels, 1000, Belgium
  • Hopital Erasme
    Brussels, 1070, Belgium
  • Hopital de Jolimont
    Haine-Saint Paul, 7100, Belgium
  • AZ Groeninge
    Kortrijk, 8500, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • CHU Mont -Godinne
    Yvoir, 5530, Belgium
  • Monte Tabor - Hospital Sao Rafael
    Salvador, Bahia 41253-190, Brazil
  • BIOCANCER - Centro de Pesquisa e Tratamento do Câncer S/A
    Belo Horizonte, Minas Gerais 30150-281, Brazil
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, Rio Grande Do Sul 90035-903, Brazil
  • Hospital Nossa Senhora da Conceicao
    Porto Alegre, Rio Grande Do Sul 91350-200, Brazil
  • Fundacao Pio XII - Hospital de Cancer de Barretos
    Barretos, São Paulo 14784-400, Brazil
  • Hospital Universitario de Brasilia
    Brasílía, 70840-050, Brazil
  • Hospital Erasto Gaertner
    Curitiba, 81520-060, Brazil
  • Pro Onco Centro de Tratamento Oncologico
    Londrina, 86050-190, Brazil
  • Hospital Israelita Albert Einstein
    Morumbi, 05651-901, Brazil
  • Instituto Estadual Arthur de Siqueira Cavalcanti - HEMORIO
    Rio de Janeiro, 20211-030, Brazil
  • Instituto Nacional de Cancer - INCA
    Rio de Janeiro, 20230-130, Brazil
  • Centro de Estudos e Pesquisas de Hematologia e Oncologia da Faculdade de Medicina do ABC
    Santo Andre, 09060-650, Brazil
  • Instituto de Ensino e Pesquisa Sao Lucas
    São Paulo, 01236-030, Brazil
  • Fundação Antonio Prudente - AC Camargo Câncer center
    São Paulo, 01509-900, Brazil
  • MHAT Georgi Stranski PlevenHematology Clinic
    Pleven, 5800, Bulgaria
  • University hospital Sveti Georgi Hematology Clinic
    Plovdiv, 4002, Bulgaria
  • Military Medical Academy
    Sofia, 1606, Bulgaria
  • National Specialized Hospital for Active Treatment of Hematology Diseases
    Sofia, 1756, Bulgaria
  • University hospital Sveta Marina
    Varna, 9010, Bulgaria
  • Regional Health Authority B-Saint John Regional Hospital
    Saint John, New Brunswick E2L 4L2, Canada
  • General Hospital, Eastern Health
    St John's, Newfoundland and Labrador A1B 3V6, Canada
  • Hospital Charles LeMoyne
    Greenfield Park, Quebec J4V2H1, Canada
  • Sacre-Couer Hospital
    Montreal, Quebec H4J 1C5, Canada
  • Instituto Oncologico
    Renaca, 2540364, Chile
  • Instituto Clinico Oncologico del Sur ICOS
    Temuco, 4810469, Chile
  • Oncomedica S.A.
    Monteria, Colombia
  • University Hospital Centre Split
    Split, 21000, Croatia
  • General Hospital Sveti Duh
    Zagreb, 10000, Croatia
  • Klinicka bolnica Dubrava Klinika za unutarnje bolesti Odjel za Hematologiju
    Zagreb, 10000, Croatia
  • University Hospital Centre Zagreb
    Zagreb, 10000, Croatia
  • University Hospital2.Dep.Intern.Med. Hematology
    Hradec Kralove, 500 05, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava, 70852, Czechia
  • Faculty Hospital Kralovske Vinohrady
    Prague, 100 00, Czechia
  • Rigshospitalet University Hospital
    Copenhagen, 2100, Denmark
  • Herlev University Hospital Dep of hematology
    Harlev, 2730, Denmark
  • Roskilde University Hospital
    Roskilde, 4000, Denmark
  • Bergonie Institut
    Bordeaux, 33076, France
  • Polyclinique Bordeaux Nord Aquitaine
    Bordeaux, 33300, France
  • CHRU
    Grenoble cedex 09, 38043, France
  • CHU Dupuytren
    Limoges, 87042, France
  • Hopital de l'Archet 1
    Nice, 06200, France
  • CHU Hautepierre
    Strasbourg, 67098, France
  • Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum
    Debrecen, 4032, Hungary
  • Kaposi Mor Oktato Korhaz
    Kaposvar, 7400, Hungary
  • Szegedi TudomanyegyetemII Belgyogyaszati Klinika
    Szeged, 6720, Hungary
  • Komarom-Esztergom Megye Onkormanyzat Szent Borbala Korhaza
    Tatabanya, Hungary
  • Petz Aladar Country Hospital
    Vasvari Pal U. 2, 9023, Hungary
  • Ha'Emek Medical Center
    Afula, 18101, Israel
  • Barzilai Medical Center
    Ashkelon, 78278, Israel
  • Soroka University Medical Center
    Beer Sheva, 84101, Israel
  • Bnei Zion Medical Center
    Haifa, 31048, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 91031, Israel
  • Meir Medical Center
    Kfar-Saba, 44281, Israel
  • Western Galilee Hospital
    Naharia, 22100, Israel
  • Rabin Medical Center
    Petach Tikva, 49100, Israel

Showing the first 100 of 165 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Chanan-Khan A, Egyed M, Robak T, Martinelli de Oliveira FA, Echeveste MA, Dolan S, Desjardins P, Blonski JZ, Mei J, Golany N, Zhang J, Gribben JG. Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). Leukemia. 2017 May;31(5):1240-1243. doi: 10.1038/leu.2017.47. Epub 2017 Jan 31. No abstract available. PubMed 28140392 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2009 to primary completion in Mar 2014, 53 months.

Results were first posted in Dec 2016, 2 years 8 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 53 months is close to that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2009
First posted
Jun 1, 2009
StartActual
Oct 13, 2009
Primary completionActual
Mar 31, 2014
CompletionActual
May 9, 2018
Results first posted
Dec 21, 2016
Last update
Jul 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00910910
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jun 1, 2009
Start date
Oct 13, 2009
Primary completion
Mar 31, 2014
Completion
May 9, 2018
Results posted
Dec 21, 2016
Last update
Jul 9, 2019

Study contacts

Jeffrey Jones, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion